- Kindeva Drug Delivery completes first registration batch at its Bridgeton facility.
- New Optima filling lines to be fully operational by 2025, increasing production capacity to over 100 million units annually.
Kindeva Drug Delivery has announced two major milestones at its Bridgeton, Missouri facility, highlighting the site’s progress in injectable fill-finish capabilities. The company completed its first registration batch on its high-volume vial line, signalling the readiness of the site to meet growing demand. This marks a critical stage in Kindeva’s planned expansion of the facility.
The Bridgeton facility, designed for high-volume injectable manufacturing, is set to receive additional equipment to further bolster its capabilities. Denis Johnson, Chief Operating Officer at Kindeva, remarked, “The completion of the first registration batch at the Bridgeton facility represents a significant milestone. This is the first of four lines planned to be installed in the next 18 months.”
Kindeva also announced that it has successfully completed Factory Acceptance Testing (FAT) for the first of two Optima syringe and cartridge filling lines. The first line is expected to be installed in November 2024, with qualification slated for Q1 2025. Both Optima lines are projected to be fully operational by the end of 2025, providing the Bridgeton facility with an annual production capacity exceeding 100 million units across vials, cartridges, and syringes.
Kindeva’s expansion aligns with the growing need for advanced contract manufacturing services in the pharmaceutical sector, particularly in sterile injectables. The facility, which is fully Annex 1 compliant, is designed to support clients across a range of injectable product types.
Overview of outsourcing trends 
